The Brazil Liver Cancer Therapeutics market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Liver cancer is a chronic and life-threatening disease which begins in cells of liver. Most of the liver cancer patients do not show the symptoms at early stages but in advanced stages. Some of the common symptoms include loss of appetite, upper abdominal pain, nausea and vomiting and yellow discoloration of skin.
A higher prevalence and demand for effective drugs is expected to drive the market growth during the forecast period. Environmental factors, alcohol consumption, smoking, and increasing urbanization are mainly responsible for its prevalence. Also, strong backing from Brazilian government for R&D funding is likely to contribute to the liver cancer market opportunities.